28 Recruiting Multiple Myeloma Clinical Trials in Alabama
Explore active multiple myeloma research studies enrolling across Alabama. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Multiple Myeloma Studies in Alabama
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
📍 University of Alabama at Birmingham - Main /ID# 151405 — Birmingham, Alabama
View Study & Checklist ➔COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
📍 University of Alabama Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 The University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
📍 Local Institution — Birmingham, Alabama
View Study & Checklist ➔Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
📍 Providence Hospital — Mobile, Alabama
View Study & Checklist ➔A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham - Main /ID# 261434 — Birmingham, Alabama
View Study & Checklist ➔A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
📍 Infirmary Health - Diagnostic & Medical Clinic (DMC) — Mobile, Alabama
View Study & Checklist ➔A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 Alabama Oncology — Birmingham, Alabama
View Study & Checklist ➔Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
📍 O Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama
View Study & Checklist ➔Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
📍 Kirklin Clinic of UAB Hospital — Birmingham, Alabama
View Study & Checklist ➔A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
📍 Clearview Cancer Institute — Huntsville, Alabama
View Study & Checklist ➔Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
📍 Kirklin Clinic of UAB Hospital — Birmingham, Alabama
View Study & Checklist ➔Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
📍 Infirmary Cancer Care — Mobile, Alabama
View Study & Checklist ➔A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
📍 UAB Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
📍 GSK Investigational Site — Mobile, Alabama
View Study & Checklist ➔